Defence Therapeutics (DTCFF)
OTHER OTC:DTCFF
Want to see DTCFF full AI Analyst Report?
DTCFF Stock Chart & Stats
$0.58
$0.06(15.36%)
At close: 4:00 PM EST
$0.58
$0.06(15.36%)
Day’s Range― - ―
52-Week Range$0.31 - $0.78
Previous CloseN/A
Volume8.00K
Average Volume (3M)599.00
Market Cap
$24.01M
Enterprise Value$33.24M
Total Cash (Recent Filing)$947.35K
Total Debt (Recent Filing)$1.49M
Price to Earnings (P/E)―
Beta-0.44
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding57,369,970
10 Day Avg. Volume40
30 Day Avg. Volume599
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-743.24
Enterprise Value/Ebitda-8.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Platform (Accum®)The Accum® platform is a durable competitive asset: a proprietary intracellular delivery technology can enhance biologic potency across multiple molecules. Platform-level IP supports program scalability, licensing opportunities, and de-risks R&D by applying the same core tech to varied indications.
Multi-program Focus In High-demand AreasA pipeline spanning oncology and infectious disease provides structural diversification. Both areas receive sustained scientific, clinical and funding attention; having ADC/immunotherapy and vaccine-applicable approaches increases long-term commercialization paths and strategic partnership appeal.
Improving Operating Performance Versus Prior YearReported reductions in annual losses and a noted improvement in free cash flow versus the prior comparable period indicate management has cut burn or improved execution. This trend, if sustained, lengthens runway and reduces near-term financing pressure versus prior year levels.
Bears Say
No Commercial RevenueThe company reports zero revenue across periods, signaling no product commercialization and making future cash generation highly uncertain. Long-term value depends entirely on successful clinical development, partnerships, or licensing rather than ongoing operating receipts.
Negative Shareholders' Equity / Balance-sheet StressNegative equity since 2024 and modest assets versus meaningful debt reduce financial flexibility and complicate leverage assessment. This condition increases reliance on dilutive financings, tightens covenant capacity, and weakens the company's ability to sustain long development timelines without external capital.
Persistent Cash Burn And Negative Operating Cash FlowConsistently negative operating cash flow (TTM ~-4.9M) shows ongoing cash burn typical of early-stage biotech. Continued negative cash generation creates runway risk, forces dependence on external funding, and can constrain ability to progress multiple programs concurrently.
Defence Therapeutics News
DTCFF FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was $0.31 and its highest was $0.78 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is $24.01M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is May 22, 2026 which is in 17 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on Feb 20, 2026. The company reported -$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.021.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 57,369,970 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DTCFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―
Ownership Overview
Options Prices
Currently, No data available
---